跳至主要内容
临床试验/ACTRN12618001273279
ACTRN12618001273279已完成未知

Risk-guided strategy for reducing readmission for Acute Decompensated Heart Failure

Baker Institute for Heart and Diabetes0 个研究点目标入组 122 人开始时间: 2018年7月27日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
122

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Prevention
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • 1. 18 years of age or older
  • 2. Emergency Department admission with a primary diagnosis of Acute Decompensated Heart Failure confirmed by the treating physicians, in accordance with the HF guidelines.

排除标准

  • 1. Unable to provide written informed consent to participate in this study
  • 2. Patients that need palliative care. Discussion with the physician and assessment of palliative care needs.
  • 3. Participating in another clinical research trial where randomisation to study arms would be unacceptable
  • 4. Patients who live in an aged care facility (eg. Nursing Home)
  • 5. Moderate to severe primary mitral or aortic valve disease
  • 6. Concomitant unstable angina, acute myocardial infarction
  • 7. Cardiac device malfunction
  • 8. Endocarditis
  • 9. Patients with Left Ventricular Assistant Device (LVAD)
  • 10. Patients with asymptomatic Left Ventricular (LV) dysfunction
  • 11. Potentially reversible LV dysfunction, such as post-partum, alcoholic cardiomyopathy, hyperthyroidism.
  • 12. Abuse of alcohol or drugs
  • 13. Concomitant terminal non-cardiac illnesses that could influence 12 month prognosis (e.g. advanced malignancy)
  • 14. Inability to acquire interpretable images (identified from baseline echo)
  • Risk-guided strategy for reducing readmission for Acute Decompensated Heart Failure,
  • 15. In the investigators opinion any other condition that may affect the safety procedures of the study. (patient and personnel)

研究者

发起方
Baker Institute for Heart and Diabetes

相似试验

Risk-guided strategy for reducing readmission for... | 临床试验